Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

SRI receives NIAID grant to develop HIV vaccine

The Scripps Research Institute has been awarded a grant expected to total more than $77 million from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

12 Jul 2012

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

BioInvent International AB today announced data from the GLACIER phase IIa study evaluating BI-204 in patients with stable atherosclerotic vascular disease. BioInvent is developing BI-204 in collaboration with Genentech, a member of the Roche Group.

11 Jul 2012

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate.

11 Jul 2012

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Human Genome Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 15, 2012 as the Prescription Drug User Fee Act (PDUFA) action date.

10 Jul 2012

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Inovio Pharmaceuticals, Inc. announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon universal influenza vaccine.

10 Jul 2012

Inspiration receives FDA clinical hold order for IB1001 phase III studies on hemophilia B

Ipsen announced today that its partner Inspiration Biopharmaceuticals Inc. (Inspiration) was notified by the Food and Drug Administration (FDA) that both clinical trials evaluating the safety and efficacy of IB1001, an investigational intravenous recombinant factor IX (rFIX) therapy for the treatment and prevention of bleeding episodes in people with hemophilia B, were placed on clinical hold.

10 Jul 2012

Adiponectin reduces depression-like symptoms in mice

A hormone with anti-diabetic properties also reduces depression-like symptoms in mice, researchers from the School of Medicine at the UT Health Science Center San Antonio reported today.

10 Jul 2012

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Inspiration Biopharmaceuticals, Inc. today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds.

9 Jul 2012

Merck, OMT announce new antibody discovery collaboration

Open Monoclonal Technology, Inc. (OMT) today announced an antibody discovery collaboration with Merck KGaA. OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats to generate antibodies against several targets selected by Merck KGaA.

9 Jul 2012

New vaccine candidate against leading cause of hospital-acquired infections

Researchers at Brigham and Women's Hospital (BWH) have discovered a new vaccine candidate for the bacterium Pseudomonas aeruginosa taking advantage of a new mechanism of immunity.

7 Jul 2012

ADCT, CRT sign agreements to develop ADCs against cancer

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT's 'warhead' and linker chemistries.

6 Jul 2012

FDC precursor cells exist in the wall of blood vessels

Chronic inflammatory conditions are extremely common diseases in humans and in the entire animal kingdom. Both in autoimmune diseases and pathogen-caused diseases, the inflamed areas are rapidly colonized by antibody producing B lymphocytes - which organize themselves in highly structured areas called "lymphoid follicles".

6 Jul 2012

Scientists use antibody injections to rapidly reverse onset of Type I diabetes in mice

Scientists at the University of North Carolina School of Medicine have used injections of antibodies to rapidly reverse the onset of Type I diabetes in mice genetically bred to develop the disease. Moreover, just two injections maintained disease remission indefinitely without harming the immune system.

6 Jul 2012

Anti-cancer activity of HuCAL antibody revealed by new data from OncoMed

MorphoSys AG's (FSE: MOR; Prime Standard Segment, TecDAX) partner OncoMed Pharmaceuticals today announced that Proceedings of the National Academy of Sciences of the United States of America (PNAS) has published online data demonstrating the potent anti-cancer activity of OMP-18R5, a HuCAL antibody targeting the Wnt pathway, in multiple preclinical human tumor models. OMP-18R5 is currently in Phase 1 clinical testing.

5 Jul 2012

Nicotine addiction: An interview with Dr. Crystal

Cigarette smoking and nicotine addiction are widespread problems throughout the world. Many people continue to smoke despite high taxes and the available public information on the dangers of smoking.

3 Jul 2012

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

Research suggests that patients with leukemia sometimes relapse because standard chemotherapy fails to kill the self-renewing leukemia initiating cells, often referred to as cancer stem cells. In such cancers, the cells lie dormant for a time, only to later begin cloning, resulting in a return and metastasis of the disease.

3 Jul 2012

Study identifies possible new approach to defeat bacterial infections

Research led by St. Jude Children's Research Hospital scientists has identified a possible new approach to defeating bacterial infections by targeting an innate immune system component in a bid to invigorate the immune response.

3 Jul 2012

FDA accepts BLA filing and grants Priority Review to ThromboGenics' ocriplasmin

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it has officially accepted the filing of the Biologics License Application for ocriplasmin intravitreal injection, 2.5 mg/ml and granted it Priority Review.

3 Jul 2012

RapidChek- SELECT Salmonella highly sensitive to the presence of S. Typhi vaccine in stool

Salmonella Typhi (S. Typhi) is the causative agent of typhoid fever, a serious health threat resulting in some 22 million new cases yearly and approximately 217,000 fatalities. A number of novel vaccine candidates using live attenuated strains of Salmonella are being developed, but care must be taken to ensure the bacteria are not excreted into the environment following vaccination.

29 Jun 2012

Researchers probe origin of optimized antibodies against infections

An organism's ability to make new antibodies and use them to optimize its own immune defenses is of central importance in the fight against pathogens. In the case of severe infections, the overall relative speed with which an immune response proceeds could mean the difference between life and death.

29 Jun 2012

Antibody News and Research

Further Reading

SRI receives NIAID grant to develop HIV vaccine

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Inspiration receives FDA clinical hold order for IB1001 phase III studies on hemophilia B

Adiponectin reduces depression-like symptoms in mice

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Merck, OMT announce new antibody discovery collaboration

New vaccine candidate against leading cause of hospital-acquired infections

ADCT, CRT sign agreements to develop ADCs against cancer

FDC precursor cells exist in the wall of blood vessels

Scientists use antibody injections to rapidly reverse onset of Type I diabetes in mice

Anti-cancer activity of HuCAL antibody revealed by new data from OncoMed

Nicotine addiction: An interview with Dr. Crystal

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

Study identifies possible new approach to defeat bacterial infections

FDA accepts BLA filing and grants Priority Review to ThromboGenics' ocriplasmin

RapidChek- SELECT Salmonella highly sensitive to the presence of S. Typhi vaccine in stool

Researchers probe origin of optimized antibodies against infections

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo